

OFFICIAL

CERTIFICATE OF MAILING OR TRANSMISSION			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office.			
Name (Print/Type)	Michael A. Moose	Centralized Fax No. 703-872-9306	
Signature	<i>Michael A. Moose</i>	Date	February 25, 2004

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	
PAUL A. SECHRIST	)	
Serial No.: 10/007,853	)	Examiner: Strickland, Jonas N.
Filed: November 5, 2001	)	Art Unit: 1754
Attorney Docket No. 106462	)	
CYCLIC CATALYST REGENERATION	)	
PROCESS USING ADSORPTION	)	
AND DESORPTION ON VENT STREAM	)	

REPLY

Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

In response to the Office action dated September 25, 2003, favorable reconsideration of the subject application is respectfully requested in view of the following remarks.

REMARKS

Claims 1-22 are pending.

Claims 1-4, 18, and 19 are objected to because they recite "selected from the group consisting of". It is believed that these claims are acceptable, since one acceptable form of alternative expression in claims is a Markush group, which recites members as being "selected from the group consisting of ...". MPEP § 2173.05(h) Alternative Limitations, I. Markush Groups. Therefore, it is submitted that these objections should be withdrawn.

10/007,853 Reply

Claims 1-22 of the subject application are provisionally rejected under 35 U.S.C. §101 as being unpatentable over claims 1-22 of copending U.S. Application No. 10/010,564 on the grounds that claims 1-22 of the subject application claim the same invention as claims 1-22 of the '564 application. This rejection should be withdrawn because claims 1-22 of the subject application do not claim the same invention as claims 1-22 of the '564 application.

Claim 1 of the subject application recites in (d) forming the regeneration inlet stream from both at least a portion of the desorption effluent stream and a second portion of the regeneration effluent stream, while claim 1 of the '564 application recites in (d) forming the regeneration inlet stream from at least a portion of the desorption effluent stream. The test for same invention is "whether one of the claims being compared could be literally infringed without literally infringing the other. If it could be, the claims cannot define identically the same invention." In re Vogel, 164 U.S.P.Q. 619, 622 (CCPA, 1970). In this case, if the regeneration inlet stream is not formed from a second portion of the regeneration effluent stream, then claim 1 of the '564 application could be literally infringed without literally infringing claim 1 of the subject application, which requires that the regeneration inlet stream be formed from a second portion of the regeneration effluent stream. Therefore, claim 1 of the subject application does not claim the same invention as claim 1 of the '564 application. Accordingly, it is believed that claim 1 of the subject application meets the requirements of 35 U.S.C. §101 and that the rejection of claim 1 of the subject application under 35 U.S.C. §101 should be withdrawn. The rejection of claims 2-15 of the subject application under 35 U.S.C. §101 should be withdrawn for the reason given in support of claim 1 of the subject application because they are dependent on claim 1 of the subject application.

Claim 16 of the subject application recites in (e) forming the regeneration inlet stream from both at least a portion of the desorption effluent stream and a second portion of the regeneration effluent stream, while claim 16 of the '564 application recites in (e) forming the regeneration inlet stream from at least a portion of the desorption effluent stream. If the regeneration inlet stream is not formed from a second portion of the regeneration effluent stream, then claim 16 of the '564 application could be literally infringed without literally infringing claim 16 of the subject application, which requires that the regeneration inlet stream be formed from a second portion of the regeneration effluent stream. Therefore, claim 16 of the subject application does not claim the same invention as claim 16 of the '564 application. Accordingly, it is believed that claim 16 of the subject application meets the requirements of 35 U.S.C. §101 and that the rejection of claim 16 of the subject application under 35 U.S.C. §101 should be withdrawn. The rejection of claims 17-22 of the subject application under 35 U.S.C. §101 should be withdrawn for the reason given in support of claim 16 of the subject application because they are dependent on claim 1 of the subject application.

Claims 1-22 are rejected under 35 U.S.C. §103(a) as being unpatentable over U.S. Patent No. 5,965,473 (Sechrist). Claim 1 recites a process comprising contacting a regeneration inlet stream with a catalyst in (a) and contacting a desorption inlet stream with an adsorbent in (c). Sechrist teaches a process in which a regenerant gas contacts catalyst in a catalyst bed in order to regenerate that catalyst and in which the contacting removes chloro-species from the catalyst. Col. 2, lines 1-8, col. 11, line 24 to col. 12, line 59, and col. 20, line 66 to col. 21, line 42. But Sechrist does not teach or suggest a process that comprises both contacting a regeneration inlet stream with a catalyst *and* contacting a desorption inlet stream with an adsorbent. In fact, Sechrist teaches away from using an adsorbent that is separate from the catalyst. Col. 2, line 19 to col. 3, line 18. Therefore, Sechrist does not motivate a person of ordinary skill in the art to contact an adsorbent with a desorption inlet stream. Accordingly, it is believed that claim 1 meets the requirements of 35 U.S.C. §103(a) and that the rejection of claim 1 under 35 U.S.C. §103(a) as being unpatentable over Sechrist should be withdrawn. The rejection of claims 2-15 under 35 U.S.C. §103(a) as being unpatentable over Sechrist should be withdrawn for the reasons given in support of claim 1 since they are dependent on claim 1. Claim 16 recites a process comprising passing a regeneration inlet stream to a catalyst bed containing a catalyst in (b) and passing a desorption inlet stream to a desorption zone containing an adsorbent in (d). The rejection of claims 16 under 35 U.S.C. §103(a) as being unpatentable over Sechrist should be withdrawn for the reasons given in support of claim 1. The rejection of claims 17-22 under 35 U.S.C. §103(a) as being unpatentable over Sechrist should be withdrawn for the reasons given in support of claim 16 since they are dependent on claim 16.

In view of the foregoing remarks, favorable reconsideration of the subject application is respectfully requested.

Respectfully submitted,

UOP LLC



Michael A. Moore  
Attorney for Applicant  
Reg. No. 41,203

02/25/04 WED 17:41 FAX 847 391 2387

UOP PATENT DPT.

FEB 25 2004

001

**OFFICIAL**

PTO/SB/21 (08-03)

Approved for use through 08/30/2003 - OMB 04151-003  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/007,853	
	Filing Date	11/05/2001	
	First Named Inventor	Paul A. Sechrist	
	Art Unit	1754	
	Examiner Name	Strickland, Jonas N.	
Total Number of Pages in This Submission	7	Attorney Docket Number	106462

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Credit Card Payment Form PTO-2034
Remarks _____		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Michael A. Moore
Signature	<i>Michael A. Moore</i>
Date	February 25, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Michael A. Moore		
Signature	<i>Michael A. Moore</i>	Date	Feb. 25, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0851-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 420)

## Compl to if Known

Application Number	10/007,853
Filing Date	11/05/2001
First Named Inventor	Paul A. Sechrist
Examiner Name	Strickland, Jonas N.
Art Unit	1754
Attorney Docket No.	106462

## METHOD OF PAYMENT (check all that apply)

☐ Check ☒ Credit card ☐ Money Order ☐ Other ☐ None  
☐ Deposit Account:  
Deposit Account Number  
Deposit Account Name

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) or any underpayment of fee(s)  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	

SUBTOTAL (1) (\$)

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims  -20\*\* =  X \$18 =   
Independent Claims  -3\*\* =  X \$86 =   
Multiple Dependent  =

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

\*\*or number previously paid, if greater. For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	420
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to Institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify) 1814 Statutory disclaimer (\$110)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 420)

## SUBMITTED BY

Name (Print/Type)	Michael A. Moore	Registration No. (Attorney/Agent)	41,203	Telephone	847-391-2948
Signature	<i>Michael A. Moore</i>	Date	Feb. 25, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OFFICIAL

CERTIFICATE OF MAILING OR TRANSMISSION			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office.			
Name (Print/Type)	Michael A. Moore	Centralized Fax #	(703) 872-9306
Signature	<i>Michael A. Moore</i>	Date	February 25, 2004

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTERIn re Application of  
Paul A. Sechrist

Serial No.: 10/007,853

Filed: 11/05/2001

Attorney Docket No. 106462

CYCLIC CATALYST REGENERATION PROCESS)  
USING ADSORPTION AND DESORPTION )  
ON VENT STREAM )

Examiner: Strickland, Jonas N.

Art Unit: 1754

Confirmation No.: 7587

FEB 25 2004

OFFICIAL

Commissioner for Patents  
Alexandria, VA 22313-1450REQUEST FOR EXTENSION OF TIME

Applicant, through their attorney, respectfully requests a two-month extension of time within which to respond to the Office action dated September 25, 2003.

A fee transmittal form, as well as authorization for credit card payment of the fee, are attached.

Respectfully submitted,

UOP LLC

*Michael A. Moore*Michael A. Moore  
Attorney for Applicant  
Reg. No. 41,203

MAM:sb

02/27/2004 AWONDAF1 00000022 10007853

01 FC:1252

420.00 0P

action as well as from about 10 to about 20 weight-% of microcrystalline cellulose (Avicel®) and other pharmaceutically acceptable adjuvants. In the cited prior art literature no mention is made of the use of Methocel E4M 4000 cps in the proposed formulations with microcrystalline cellulose and glycerol ditripalmitostearate for hygroscopic and also for non-hygroscopic therapeutic agents. This combination is particularly advantageous for the preparation of sustained release systems of the present invention and in clinical tests it shows a bioavailability which is comparable with or superior to that of the known commercial preparations. No prior chemical or physical treatment of hydroxypropylmethylcellulose as proposed in some instances in the cited prior art is necessary for manufacturing the tablets of the present invention. Upon addition of the therapeutic agent and other ingredients, the mixture has an excellent compressibility and the tablets prepared therefrom are hard, stable and of low friability and provide a slow release rate of the therapeutic agent. The tableting of some therapeutic agents can be achieved by direct compressing without prior granulation, e.g. in the manufacture of aminophylline and propranolol hydrochloride sustained release tablets. For the manufacture of sustained release tablets of the present invention, various hygroscopic and non-hygroscopic therapeutic agents can be used, e.g. antiinflammatory substances (ketoprofen, indometacine, ibuprofen), coronary and cerebral vasodilators, peripheral vasodilators, anti-infectives, psychotropics and antimanics (lithium carbonate), antihistamines and anti-ulcus substances, laxatives, anti-arrhythmics and anti-hypertensive drugs (propranolol hydrochloride), diuretics and drugs used in the treatment of migraine (dihydroergotamine mesylate) and many others.

It was found that sustained release tablets can be obtained by compressing high viscosity grade, i.e. high molecular weight hydroxypropylmethylcellulose (Methocel E4M, 4000 cps, Premium), microcrystalline cellulose, optionally glycerol ditripalmitostearate and other fillers, and the therapeutic agent in definite proportions. When the tablet is brought in contact with water or digestive fluids, a certain percentage of the therapeutic agent is rapidly released from the preparation into the solvent. The hydration and the swelling of cellulose take place on the contact surface of the tablet with water and a gel barrier is formed. The rest of the therapeutic agent is then released more slowly, depending on the diffusion rate across the gel barrier and/or on its attrition.

The method for manufacturing sustained release tablets is based either on direct tableting or on previous dry or wet preparation of granules, which comprises thoroughly blending the hydroxypropylmethylcellulose carrier with the therapeutic agent in powdery or granular form, optionally with glycerol ditripalmitostearate and the remaining conventional adjuvants used in the tablet manufacture, e.g. magnesium stearate, lactose, starch, i.e. binding, filling and swelling agents etc. The ingredients are compressed in conventional tableting machines to give products of desired shape, weight, hardness and low friability, thus providing for the desired prolonged release of the therapeutic agent within a period of up to 12 hours, depending on the shape and the hardness of the tablets and particularly on the carrier. Thus it is possible to produce long-acting or sustained release tablets in a relatively simple and economical manner.

The following illustrative Examples are not to be considered limitative.

#### Example 1

Sustained release 350 mg aminophylline tablets (retard tablets) containing 27.8 % Methocel E4M, 4000 cps, Premium, are prepared from untreated Methocel E4M.

The 350 mg aminophylline tablets are prepared from the following ingredients:

Ingredients	mg/tablet	%
Aminophylline anhydrous	350.0 mg	54.68
Microcrystalline cellulose (Avicel)	74.0 mg	11.56
Aerosil 200	6.5 mg	1.01
Precirol Ato 5 Gattefossé	18.0 mg	2.81
Magnesium stearate	5.5 mg	0.85
Dye FD & C 5 Yellow Al. lake	8.0 mg	1.25
Methocel E4M, Premium	ad 640.0 mg	27.8

## Note:

Precirol Ato 5 (Gattefossé) is the commercial designation for glycerol ditrpalmitostearate. Methocel E4M Premium is the designation of hydroxypropylmethylcellulose 4000 cps. Aerosil 200 is the designation for high purity  $\text{SiO}_2$  (see H.P. Fiedler Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete, 2nd Edition 1981; Editio Cantor, Aulendorf, West Germany). The dye FD & C 5 Yellow Al. lake (Capsugel AG, Basel) is on the tartrazine basis.

The anhydrous aminophylline, Methocel E4M, the dye, a part of Precirol, Aerosil and magnesium stearate are passed through an appropriate sieve and after the mixing the mixture is shaped into briquettes. The briquettes are ground to the desired granulation. To the granulate the remaining microcrystalline cellulose (Avicel), Precirol and magnesium stearate are added and mixed. The thus obtained granulate is compressed to tablets of desired shape, weight and hardness, whereby an adequate release of the therapeutic agent is achieved.

15 Test ResultsStability

The results of the analyses of accelerated and current stability tests demonstrate that the solid drug unit dosage form of sustained release 350 mg aminophylline tablets on the hydroxypropylmethylcellulose, type Methocel E4M Premium, carrier base material meets the requirements with respect to both the therapeutic agent release from the tablet and the chemical and physical stability over the whole storage time, as it is evident from the following tables with test results.

Table 1

Storage time (months)	+Storage conditions				++Storage conditions			
	20±5°C	40±1°C	50±1°C	25°C 80% rel. humidity	20±5°C	40±1°C	50±1°C	25°C 80% rel. humidity
0	100.0%	-	-	-	100.0%	-	-	-
3	99.5%	99.2%	99.7%	-	100.0%	96.5%	95.0%	-
6	99.9%	99.7%	99.2%	96.1%	99.5%	95.3%	93.8%	95.9%
12	101.1%	98.9%	97.5%	-	98.1%	91.0%	86.7%	-
24	98.5%	-	-	96.7%	96.4%	-	-	96.2%
37	97.8%	-	-	95.8%	96.7%	-	-	95.8%

+ Content: anhydrous theophylline; declared content =  
300.0 mg (100 %)

++ Content: ethylene diamine; initial content = 52.22 mg  
(100 %)

Note: The results are expressed as a mean value of four determinations.



Hardness (N)

Apparatus: Erweka BT, producer Erweka-Apparatebau GmbH, Heuenstamm, Kr. Offenbach Main, West Germany

Table 2

Storage time (months)	Storage conditions $20 \pm 5^{\circ}\text{C}$
0	53.9 - 78.4 N
3	53.9 - 78.4 N
6	58.8 - 78.4 N
12	53.9 - 88.2 N
37	44.1 - 78.4 N

The results are given for 10 tablets from minimum to maximum hardness.

Dissolution (release rate)

350 mg aminophylline tablets containing 300 mg of the therapeutic agent theophylline.  
Storage conditions: blister - room temperature.

Apparatus: apparatus 3 (USP XX).

Medium: artificial gastric and intestinal fluids, 600 ml.

Temperature:  $37^{\circ}\text{C}$ .

Quantitative analysis: UV spectrophotometry, 275 nm.

Requirement: after 1 hour: 10-30 %

after 3.5 hours: 45-75 %

after 7 hours: 80 %

Table 3

Time (hrs)	% of released theophylline		
	analysis 1	analysis 2	analysis 3
1	15.7%	15.5%	15.2%
3.5	58.6%	54.3%	52.0%
7	89.0%	85.1%	84.0%

The foregoing tables demonstrate that even after prolonged storage at elevated temperatures sustained release aminophylline tablets remain practically unaltered, which assures a shelf life of 3 years at a temperature up to  $25^{\circ}\text{C}$ .

In vitro release rate of theophylline from sustained release 350 mg aminophylline tablets (A) of the aforesaid composition and from the commercial preparation sustained release 350 mg Phyllocontin® forte tablets (P)

Apparatus 3 (USP XX).

Medium: artificial gastric and intestinal fluids, free of enzymes (USP XXI), 600 ml.

Temperature: 37°C.

Quantitative analysis: UV spectrophotometry, 275 nm.

5	Time (h)	% of released theophylline ( $\bar{X}$ , n=6)	
		A	P
	1	22.1	17.9
10	2	35.4	32.6
	3.5	58.5	59.4
	5	75.0	79.7
15	7	85.9	93.4

## Sustained release 350 mg Aminophylline tablets (A)

20		$C_{max}$ ( $\mu\text{g/ml}$ )	$t_{max}$ (h)	$AUC^{0-24}$ ( $\mu\text{g}\cdot\text{h/ml}$ )	$AUC^{0-\infty}$ ( $\mu\text{g}\cdot\text{h/ml}$ )
	mean	4.925	4.4	73.42	116.09
25	range	3.536-6.735	3-6	49.57-103.50	72.21-164.89
	No. of s.	10	10	10	10

## Sustained release 350 mg Phyllocontin forte tablets (P)

30		$C_{max}$ ( $\mu\text{g/ml}$ )	$t_{max}$ (h)	$AUC^{0-24}$ ( $\mu\text{g}\cdot\text{h/ml}$ )	$AUC^{0-\infty}$ ( $\mu\text{g}\cdot\text{h/ml}$ )
35	mean	4.301	5.3	68.75	100.64
	range	3.076-6.559	2-8	41.58-122.70	55.19-187.52
40	No. of s.	10	10	10	10

## Note:

 $C_{max}$  = maximal concentration of therapeutic agent in blood $t_{max}$  = time to maximal concentration of therapeutic agent in blood

AUC = area under the plasma concentration of therapeutic agent curve

No. of s. = number of subjects

The comparison preparation for sustained release 350 mg aminophylline tablets was the commercial preparation sustained release 350 mg Phyllocontin® forte tablets. The plasma concentration curve has a form suitable for a sustained release formulation. The pharmacokinetic parameters do not differ statistically significantly.

Example 2

Sustained release 150 mg ketoprofen tablets containing 25.9 % Methocel E4M, Premium, 4000 cps, are prepared from untreated Methocel E4M.

The tablets are prepared from the following ingredients:

	Ingredients	mg/tablet	%
5	Ketoprofen	150.0 mg	51.72
	Methocel E4M, 4000 cps, Premium	65.0 mg	22.41
	microcrystalline cellulose (Avicel)	62.5 mg	21.55
10	magnesium stearate	3.0 mg	1.03
	Aerosil 200	2.0 mg	0.68
	polyvinylpyrrolidone K 25	7.5 mg	2.58

15 Ketoprofen and microcrystalline cellulose (Avicel) are mixed and then passed through an appropriate sieve. A part of Aerosil and of magnesium stearate are added to the mixture, which is then granulated with polyvinylpyrrolidone K 25. The granules are dried, passed through an appropriate sieve, then Methocel E4M Premium, the remaining Aerosil and magnesium stearate are added and mixed. The obtained granulate is tableted to tablets of desired shape, weight and hardness, whereby an appropriate release of the active  
20 ingredient is achieved.

#### Test results

#### 25 Stability

Table 1: Ketoprofen content

30 Initial content: 149.7 mg/tablet = 100.0 %

Storage time (days)	Storage conditions					
	4 $\pm$ 1 $^{\circ}$ C	20 $\pm$ 5 $^{\circ}$ C	30 $\pm$ 1 $^{\circ}$ C	40 $\pm$ 1 $^{\circ}$ C	50 $\pm$ 1 $^{\circ}$ C	80% 25 $\pm$ 1 $^{\circ}$ C
35 92	101.1%	100.9%	100.0%	97.9%	94.4%	98.7%
186	100.9%	99.2%	98.3%	98.6%	95.9%	99.3%
356	100.4%	98.8%	99.7%	99.8%	-	99.8%

Table 2: Hardness of the tablets (N)

Apparatus: Erweka BT  
45 Initial value: 34.3-78.4 N

Storage time (days)	Storage conditions		
	4 $^{\circ}$ $\pm$ 1 $^{\circ}$ C	20 $^{\circ}$ $\pm$ 5 $^{\circ}$ C	30 $^{\circ}$ $\pm$ 1 $^{\circ}$ C
50 92	34.3 - 44.1	44.1 - 58.8	53.9 - 63.7
186	39.2 - 53.9	39.2 - 53.9	58.8 - 68.6
356	53.9 - 63.7	49.0 - 63.7	58.8 - 68.6

Table 3: Dissolution test (release rate)

Sustained release 150 mg ketoprofen tablets  
 Storage conditions: small bottle - room temperature  
 5 Apparatus 1 (USP XXI): 100 rpm  
 Medium: artificial gastric and intestinal fluids, 1000 ml  
 Temperature: 37°C  
 Quantitative analysis: UV spectrophotometry, 258 nm  
 Requirement: after 1 hour: 10-30 %  
 10 after 4 hours: 30-60 %  
 after 8 hours: 50-75 %  
 after 12 hours: > 70 %

Time (hrs)	% of released ketoprofen		
	analysis 1	analysis 2	analysis 3
1	21.6	21.3	20.7
4	54.1	53.1	52.8
8	73.4	71.2	72.5

25 On the basis of the accelerated stability test results it can be concluded that sustained release 150 mg ketoprofen tablets are stable and that at the temperature of up to 25°C there can be assumed a shelf life of 5 years.

In vitro dissolution or release rate of ketoprofen from tablets (50.0 mg) and from sustained release 150 mg ketoprofen tablets with aforesaid composition.

30 Apparatus 1 (USP XXI): 100 rpm  
 Medium: phosphate buffer, pH 5.7, 900 ml  
 Temperature: 37°C  
 Quantitative analysis: UV spectrophotometry, 258 nm

Time (min)	% of ketoprofen released from tablets (n=6)
5	59.6
15	91.6
30	96.5

45 Apparatus 1 (USP XXI): 100 rpm  
 Medium: artificial gastric and intestinal fluid, free of enzymes (USP XXI), 1000 ml  
 Temperature: 37°C  
 Quantitative analysis: UV spectrophotometry, 258 nm

Time (hrs)	% of ketoprofen released from sustained release ketoprofen tablets (n=6)
1	19.1
4	48.8
8	63.7
12	76.5

Samples of sustained release 150 mg ketoprofen tablets were tested in vivo in humans and compared with two 50 mg ketoprofen tablets after a single application. The results are given in the following table:

Type of tablets	Time to maximal concentration (hrs)	Maximal concentration (mg/l)	Total area under the curve (mg.h/l)
<u>Sustained release</u>			
150 mg tablets			
mean	5.44	2.31	26.1
range	(2.0-12.0)	(1.39-3.49)	(15.5-42.3)
No. of subjects	9	9	9
<u>Conventional tablets</u>			
2 x 50 mg			
mean	1.48	9.65	21.20
range	(0.67-3.00)	(6.30-15.20)	(17.27-30.99)
No. of subjects	8	8	8

The table clearly demonstrates the influence of prolonged release from the sustained release form upon the ketoprofen pharmacokinetics, which allows the number of application to be reduced to 1-2 daily.

### Example 3

Sustained release 160 mg propranolol hydrochloride tablets containing 36.2 % Methocel E4M Premium, 4000 cps, are prepared from untreated Methocel E4M. The tablets are prepared from the following ingredients:

Ingredients	mg/tablet	%
Propranolol hydrochloride	160	46.38
Methocel E4M, 4000 cps, Premium	125	36.23
microcrystalline cellulose	45.2	13.10
Precirol ATO 5	9.9	2.87
Aerosil 200	3.3	0.96
magnesium stearate	1.6	0.46

Sustained release propranolol tablets were prepared by briquetting the ingredients, followed by domminuting the briquettes, sieving throuhg an appropriate size sieve and forming a granulate.

The resulting granulate is homogenously mixed under the addition of an appropriate lubricant and again passed through a sieve.

The thus obtained granulate is tableted to tablets of desired shape, weight and hardness, whereby an appropriate release of the therapeutic agent is achieved.

### Test results

StabilityTable 1: Propranolol hydrochloride content

Initial content: 160 mg propranolol hydrochloride  
per tablet = 100.0 %

Storage time (days)	Storage conditions					
	4 $\pm$ 1°C	20 $\pm$ 5°C	30 $\pm$ 1°C	40 $\pm$ 1°C	50 $\pm$ 1°C	80 % humidity (25°C)
126	99.1%	100.6%	99.8%	100.0%	99.9%	99.7%
220	100.7%	99.0%	100.7%	100.3%	100.8%	100.2%
380	99.5%	100.0%	99.3%	99.0%	100.0%	99.6%

Table 2: Hardness of the tablets (N)

Apparatus: Erweka BT  
Initial value: 39.2 - 68.6 N

Storage time (days)	Storage conditions		
	4° $\pm$ 1°C	20° $\pm$ 5°C	30° $\pm$ 1°C
126	58.8 - 68.6	63.7 - 68.6	63.7 - 73.5
220	49.0 - 63.7	44.1 - 73.5	58.8 - 73.5
380	73.5 - 88.2	73.5 - 88.2	78.4 - 88.2

Table 3: Dissolution test (release rate)

Propranolol hydrochloride: 160 mg tablets  
Storage conditions: blister - room temperature  
Apparatus 3 (USP XX)

Medium: artificial gastric fluid and intestinal fluids free of enzymes (USP XXI), 600 ml  
Temperature: 37°C

Quantitative analysis: UV spectrophotometry, 286 nm

Requirement: after 1 hour: 10-30 %

after 4 hours: 40-75 %

after 8 hours: > 75 %

Time (hrs)	% of released propranolol hydrochloride				
	analysis 1	analysis 2	analysis 3	analysis 4	analysis 5
1	26.8	22.0	22.5	22.8	22.5
2	41.4	35.4	37.0	37.2	35.9
4	62.9	56.3	56.5	57.7	56.0
6	78.2	73.1	70.6	74.1	71.8
8	88.8	83.4	81.1	83.7	84.0

On the basis of accelerated stability test results it was found that sustained release 160 mg propranolol hydrochloride tablets are stable and at the temperature of 25°C a shelf life of 3 years can be assured.

In vitro release rate of propranolol hydrochloride from sustained release 160 mg tablets with aforesaid composition (P) and from the commercial preparation sustained release 160 mg Inderal® tablets (I).

Apparatus 3 (USP XX)

Medium: artificial gastric and intestinal fluids free of enzymes (USP XXI), 600 ml

Temperature: 37°C

Quantitative analysis: UV spectrophotometry, 286 nm

Time (hrs)	% of released propranolol hydrochloride	
	P	I
1	19.5	17.0
2	31.8	35.2
4	50.3	56.2
6	65.5	69.0
8	77.3	77.4

Sustained release 160 mg propranolol hydrochloride tablets

	$t_{\max}$ (h)	$C_{\max}$ (ng/ml)	$AUC^{0-24}$ (ng.h/ml)	$AUC^{0-\infty}$ (ng.h/ml)
mean	5.0	22.09	292.29	492.92
range	2.0-13.8	11.10-41.50	134.68-727.70	194.64-1695.31
No. of s.	8	8	8	8

Sustained release 160 mg Inderal<sup>R</sup> tablets

	$C_{\max}$ (ng/ml)	$t_{\max}$ (h)	$AUC^{0-24}$ (ng.h/ml)	$AUC^{0-\infty}$ (ng.h/ml)
mean	16.64	6.75	20.60	389.71
range	4.30-25.40	5-12	73.10-383.23	163.74-1376.28
No. of s.	8	8	8	8

Note:

- $C_{\max}$  = maximal concentration of therapeutic agent in blood  
 $t_{\max}$  = time to maximal concentration of therapeutic agent in blood  
 $AUC$  = area under the plasma concentration of therapeutic agent curve  
 No. of s. = number of subjects

The comparison preparation for sustained release 160 mg propranolol hydrochloride tablets were sustained release 160 mg Inderal<sup>®</sup> tablets. The above results demonstrate the superior bioavailability of sustained release propranolol tablets (approximately 25 %, as calculated from  $AUC^{0-\infty}$ ). The plasma concentration diagrams are suitable for a sustained release form.

Claims

1. Sustained release tablets comprising a therapeutic active agent and a carrier base material, characterized in that the carrier base material comprises hydroxypropylmethylcellulose having a methoxyl content of 28 to 30 weight-%, a hydroxypropoxyl content of 7.5 to 12 weight-% and an average molecular weight of at least 50 000, in a proportion of about 20 to about 40 weight-% of the tablet, optionally up to 10 weight-% of glycerol ditripalmitostearate and from about 10 to about 20 weight-% of microcrystalline cellulose and other conventional pharmaceutically acceptable adjuvants.



2. Sustained release tablets as claimed in claim 1, characterized in that the therapeutic agent is selected from, yet not limited to aminophylline, theophylline, ketoprofen, propranolol hydrochloride, dihydroergotamine and other ergot alkaloids in the form of acid addition salts, glyceryl trinitrate, isosorbide dinitrate and lithium carbonate.

5 3. A process for the manufacture of sustained release tablets as claimed in claim 1, characterized in that a mixture of a therapeutic agent and a carrier base material, comprising hydroxypropylmethylcellulose having a methoxyl content of 28 to 30 weight-%, a hydroxypropoxyl content of 7.5 to 12 weight-% and an average molecular weight of at least 50 000 in a proportion of about 20 to about 40 weight-% of the tablet, optionally up to 10 weight-% of glycerol ditripalmitostearate and from about 10 to about 20 weight-% of  
10 microcrystalline cellulose and other conventional pharmaceutically acceptable adjuvants, is compressed and shaped.

4. A process for the manufacture of sustained release tablets as claimed in claim 3, characterized in that the therapeutic agent is selected from, yet not limited to aminophylline, theophylline, ketoprofen, propranolol hydrochloride, dihydroergotamine and other ergot alkaloids in the form of acid addition salts,  
15 glyceryl trinitrate, isosorbide dinitrate and lithium carbonate.

20

25

30

35

40

45

50

55



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 88 10 3715

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
P,X	GB-A-2 181 053 (SANDOZ LTD) * Page 2, line 8 - page 3, line 46; examples 17,20 * ---	1,3	A 61 K 9/22 A 61 K 9/26
Y	GB-A-2 170 407 (SANDOZ LTD) * Page 1, line 1 - page 3, line 55 * ---	1-4	
Y	EP-A-0 156 592 (AMERICAN HOME PRODUCTS CORP.) * Page 5, line 3 - page 6, line 26 * -----	1-4	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			A 61 K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 27-06-1988	Examiner TZSCHOPPE, D. A.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	